Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells

Journal of Cellular Physiology

Volumn 230, Issue 3, 2015, Pages 578-586

  Cheng, Ying Hua ^a   Streicher, Drew A ^a   Waning, David L ^a   Chitteti, Brahmananda R ^a   Gerard O'Riley, Rita ^a   Horowitz, Mark C ^b   Bidwell, Joseph P ^a   Pavalko, Fredrick M ^a   Srour, Edward F ^a   Mayo, Lindsey D ^a   Kacena, Melissa A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SYNAPTOPHYSIN; MDM2 PROTEIN, HUMAN; PROTEIN MDM2;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL LINEAGE; CELL PROLIFERATION; CELL STIMULATION; ENZYME ACTIVATION; MEGAKARYOCYTE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOPROGENITOR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; HUMAN; METABOLISM;

CELL CYCLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MAP KINASE SIGNALING SYSTEM; MEGAKARYOCYTES; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION;

EID: 84920933828     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24774     Document Type: Article

References (67)

1. Berman SD, Yuan TL, Miller ES, Lee EY, Caron A, Lees JA. 2008. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 6:1440-1451.
2. Bremner R, Du DC, Connolly-Wilson MJ, Bridge P, Ahmad KF, Mostachfi H, Rushlow D, Dunn JM, Gallie BL. 1997. Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma. Am J Hum Genet 61:556-570.
3. Centrella M, McCarthy TL, Canalis E. 1991. Glucocorticoid regulation of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol 11:4490-4496.
4. Chagraoui H, Wendling F, Vainchenker W. 2006. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. Best Pract Res Clin Haematol 19:399-412.
5. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061.
6. Chen J, Lin J, Levine AJ. 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1:142-152.
7. Cheng L, Qasba P, Vanguri P, Thiede MA. 2000. Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol 184:58-69.
8. Cheng YH, Hooker RA, Nguyen K, Gerard-O'Riley R, Waning DL, Chitteti BR, Meijome TE, Chua HL, Plett AP, Orschell CM, Srour EF, Mayo LD, Pavalko FM, Bruzzaniti A, Kacena MA. 2013. Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation. J Bone Miner Res 28:1434-1445.
9. Ciovacco WA, Cheng YH, Horowitz MC, Kacena MA. 2010. Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation. J Cell Biochem 109:774-781.
10. Ciovacco WA, Goldberg CG, Taylor AF, Lemieux JM, Horowitz MC, Donahue HJ, Kacena MA. 2009. The role of gap junctions in megakaryocyte-mediated osteoblast proliferation and differentiation. Bone 44:80-86.
11. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B. 1990. P53 Functions as a Cell Cycle Control Protein in Osteosarcomas. Mol Cell Biol 10:5772-5781.
12. Dominici M, Rasini V, Bussolari R, Chen X, Hofmann TJ, Spano C, Bernabei D, Veronesi E, Bertoni F, Paolucci P, Conte P, Horwitz EM. 2009. Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood 114:2333-2343.
13. Drachman JG, Sabath DF, Fox NE, Kaushansky K. 1997. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 89:483-492.
14. Freedman DA, Levine AJ. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18:7288-7293.
15. Frey BM, Rafii S, Crystal RG, Moore MA. 1998a. Adenovirus long-term expression of thrombopoietin in vivo: a new model for myeloproliferative syndrome and osteomyelofibrosis. Schweiz Med Wochenschr 128:1587-1592.
16. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. 1998b. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 160:691-699.
17. Frum R, Ramamoorthy M, Mohanraj L, Deb S, Deb SP. 2009. MDM2 controls the timely expression of cyclin A to regulate the cell cycle. Mol Cancer Res 7:1253-1267.
18. Geyer RK, Yu ZK, Maki CG. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2:569-573.
19. Gjetting T, Lukas J, Bartek J, Strauss M. 1995. Regulated expression of the retinoblastoma susceptibility gene in mammary carcinoma cells restores cyclin D1 expression and G1-phase control. Biol Chem Hoppe Seyler 376:441-446.
20. Goodrich DW, Lee WH. 1992. Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53. Nature 360:177-179.
21. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. 1991. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-302.
22. Hartwell LH, Kastan MB. 1994. Cell cycle control and cancer. Science 266:1821-1828.
23. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
24. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. 1992. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006.
25. Hollingsworth RE, Jr., Chen PL, Lee WH. 1993a. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr Opin Cell Biol 5:194-200.
26. Hollingsworth RE, Jr., Hensey CE, Lee WH. 1993b. Retinoblastoma protein and the cell cycle. Curr Opin Genet Dev 3:55-62.
27. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
28. Horowitz MC, Fields A, DeMeo D, Qian HY, Bothwell AL, Trepman E. 1994. Expression and regulation of Ly-6 differentiation antigens by murine osteoblasts. Endocrinology 135:1032-1043.
29. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S, Lu X. 1999. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3:181-193.
30. Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EY, Lee WH. 1988. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563-1566.
31. Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. 2006. Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem 281:16814-16820.
32. Jilka RL, Cohn DV. 1981. Role of phosphodiesterase in the parathormone-stimulated adenosine 3', 5'-monophosphate response in bone cell populations enriched in osteoclasts and osteoblasts. Endocrinology 109:743-747.
33. Kacena MA, Eleniste PP, Cheng Y-H, Huang S, Shivanna M, Meijome TE, Mayo LD, Bruzzaniti A. 2012. Megakaryocytes regulate the expression of Pyk2 isoforms and the caspase-mediated cleavage of actin in osteoblasts. J Biol Chem 287:17257-17268.
34. Kacena MA, Gundberg CM, Nelson T, Horowitz MC. 2005. Loss of the transcription factor p45 NF-E2 results in a developmental arrest of megakaryocyte differentiation and the onset of a high bone mass phenotype. Bone 36:215-223.
35. Kacena MA, Nelson T, Clough ME, Lee SK, Lorenzo JA, Gundberg CM, Horowitz MC. 2006. Megakaryocyte-mediated inhibition of osteoclast development. Bone 39:991-999.
36. Kacena MA, Shivdasani RA, Wilson K, Xi Y, Troiano N, Nazarian A, Gundberg CM, Bouxsein ML, Lorenzo JA, Horowitz MC. 2004. Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2. J Bone Miner Res 19:652-660.
37. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
38. Lemieux JM, Horowitz MC, Kacena MA. 2010. Involvement of integrins alpha(3) beta(1) and alpha(5) beta(1) and glycoprotein IIb in megakaryocyte-induced osteoblast proliferation. J Cell Biochem 109:927-932.
39. Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, Stein GS, Lian JB, Jones SN. 2006. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172:909-921.
40. Leveillard T, Wasylyk B. 1997. The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem 272:30651-30661.
41. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
42. Lennert K, Nagai K, Schwarze EW. 1975. Patho-anatomical features of the bone marrow. Clin Haematol 4:331-351.
43. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. 2003. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302:1972-1975.
44. Mayo LD, Donner DB. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98:11598-11603.
45. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 87:6166-6170.
46. Miao D, Murant S, Scutt N, Genever P, Scutt A. 2004. Megakaryocyte-bone marrow stromal cell aggregates demonstrate increased colony formation and alkaline phosphatase expression in vitro. Tissue Eng 10:807-817.
47. Olson TS, Caselli A, Otsuru S, Hofmann TJ, Williams R, Paolucci P, Dominici M, Horwitz EM. 2013. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after radioablative conditioning. Blood 121:5238-5249.
48. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424:223-228.
49. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao ZX. 2005. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20:699-708.
50. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, Xiao ZX. 2004. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 279:53317-53322.
51. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. 1997. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 16:3965-3973.
52. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, Jackson CW, Hunt P, Saris CJ, Orkin SH. 1995. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81:695-704.
53. Simmons DJ, Kent GN, Jilka RL, Scott DM, Fallon M, Cohn DV. 1982. Formation of bone by isolated, cultured osteoblasts in millipore diffusion chambers. Calcif Tissue Int 34:291-294.
54. Srour EF, Brandt JE, Leemhuis T, Ballas CB, Hoffman R. 1992. Relationship between cytokine-dependent cell cycle progression and MHC class II antigen expression by human CD34+ HLA-DR- bone marrow cells. J Immunol 148:815-820.
55. Suva LJ, Hartman E, Dilley JD, Russell S, Akel NS, Skinner RA, Hogue WR, Budde U, Varughese KI, Kanaji T, Ware J. 2008. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol 172:430-439.
56. Thiele J, Kvasnicka HM, Fischer R. 1999. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification. Ann Hematol 78:495-506.
57. Towler DA, St. Aarnaud R. 2002. Use of cultured osteoblastic cells to identify and characterize transcriptional regulatory complexes. In: Bilezikian JP Raisz LG Rodan GA, editor. Principles of bone biology. San Diego, CA: Academic Press. pp 1503-1527.
58. Trimarchi JM, Lees JA. 2002. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3:11-20.
59. Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, Cramer EM, Vainchenker W, Wendling F. 1997. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90:4369-4383.
60. Weber HO, Ludwig RL, Morrison D, Kotlyarov A, Gaestel M, Vousden KH. 2005. HDM2 phosphorylation by MAPKAP kinase 2. Oncogene 24:1965-1972.
61. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81:323-330.
62. Wong GL, Cohn DV. 1975. Target cells in bone for parathormone and calcitonin are different: enrichment for each cell type by sequential digestion of mouse calvaria and selective adhesion to polymeric surfaces. Proc Natl Acad Sci U S A 72:3167-3171.
63. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
64. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. 2004. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118:83-97.
65. Yan XQ, Lacey D, Fletcher F, Hartley C, McElroy P, Sun Y, Xia M, Mu S, Saris C, Hill D, Hawley RG, McNiece IK. 1995. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86:4025-4033.
66. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, McNiece IK. 1996. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 88:402-409.
67. Ying H, Xiao ZX. 2006. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 5:506-508.